Clinical Trial Update: The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating everolimus for reducing total native kidney volume in recipients with autosomal dominant polycystic kidney disease after transplantatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Autosomal Dominant Polycystic Kidney Disease | Phase 3 | Status: COMPLETED